Alnylam Pharmace. buy Citigroup Inc.
Summary
This prediction is currently active. The BUY prediction by Citigroup_Inc_ for Alnylam Pharmace. is performing very badly with a performance of -34.63%. This prediction currently runs until 02.09.26. The prediction end date can be changed by Citigroup_Inc_ at any time. Citigroup_Inc_ has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | 0.926% | 0.926% |
| iShares Core DAX® | 0.878% | 1.051% |
| iShares Nasdaq 100 | 0.753% | 4.664% |
| iShares Nikkei 225® | 5.519% | 15.411% |
| iShares S&P 500 | 0.236% | 1.683% |
Comments by Citigroup_Inc_ for this prediction
In the thread Alnylam Pharmace. diskutieren
Stopped prediction by Citigroup_Inc_ for Alnylam Pharmace.
Alnylam Pharmace.
21.03.25
21.03.26
22.03.26
Alnylam Pharmace.
02.08.24
02.08.25
03.08.25
Alnylam Pharmace.
25.06.24
25.06.25
26.06.25
Alnylam Pharmace.
16.02.24
16.02.25
17.02.25

